GPT and pneumonia: Overall, dose interruption due to TEAEs was required in 4 of 13 patients, including 2 patients in cohort 1 (elevated ALT, AST and subsequent pneumonia in one patient, and hematuria in the other), 1 in cohort 2 (anemia, worsened hypertension, dysphagia, and pneumonia aspiration), and 1 in cohort 3 (worsened coronary artery disease).